FY2025 Earnings Estimate for Nektar Therapeutics (NASDAQ:NKTR) Issued By Zacks Research

Nektar Therapeutics (NASDAQ:NKTR – Get Rating) – Equities researchers at Zacks Research issued their FY2025 earnings estimates for Nektar Therapeutics in a report issued on Tuesday, March 14th. Zacks Research analyst K. Shah forecasts that the biopharmaceutical company will post earnings per share of ($1.01) for the year. The consensus estimate for Nektar Therapeutics’ current full-year earnings is ($0.89) per share.

Nektar Therapeutics (NASDAQ:NKTR – Get Rating) last posted its quarterly earnings data on Tuesday, February 28th. The biopharmaceutical company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.11. Nektar Therapeutics had a negative net margin of 399.98% and a negative return on equity of 76.92%. The business had revenue of $22.02 million for the quarter, compared to analyst estimates of $22.21 million. During the same quarter last year, the business earned ($0.79) earnings per share. The business’s revenue for the quarter was down 11.9% on a year-over-year basis.

Other research analysts have also issued research reports about the stock. SVB Securities decreased their price target on shares of Nektar Therapeutics from $5.00 to $3.00 in a research report on Friday, February 24th. Jefferies Financial Group lowered shares of Nektar Therapeutics from a “hold” rating to an “underperform” rating and decreased their price target for the stock from $3.20 to $1.50 in a research report on Friday, February 24th. StockNews.com started coverage on shares of Nektar Therapeutics in a research report on Thursday. They issued a “hold” rating on the stock. SVB Leerink decreased their price target on shares of Nektar Therapeutics from $5.00 to $3.00 and set a “market perform” rating on the stock in a research report on Friday, February 24th. Finally, Oppenheimer decreased their price target on shares of Nektar Therapeutics from $5.00 to $3.00 and set a “market perform” rating on the stock in a research report on Monday, March 6th. Three research analysts have rated the stock with a sell rating and four have assigned a hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $3.08.

Nektar Therapeutics Price Performance

NASDAQ NKTR opened at $0.98 on Friday. Nektar Therapeutics has a 12 month low of $0.96 and a 12 month high of $6.40. The firm has a market capitalization of $185.47 million, a PE ratio of -0.50 and a beta of 1.10. The company’s 50 day simple moving average is $2.30 and its 200 day simple moving average is $2.93.

Institutional Investors Weigh In On Nektar Therapeutics

A number of institutional investors have recently modified their holdings of NKTR. BlackRock Inc. boosted its stake in shares of Nektar Therapeutics by 11.0% during the 3rd quarter. BlackRock Inc. now owns 35,050,519 shares of the biopharmaceutical company’s stock valued at $112,159,000 after buying an additional 3,477,606 shares during the period. State Street Corp boosted its stake in shares of Nektar Therapeutics by 50.5% during the 2nd quarter. State Street Corp now owns 8,728,968 shares of the biopharmaceutical company’s stock valued at $33,170,000 after buying an additional 2,928,666 shares during the period. Vanguard Group Inc. boosted its stake in shares of Nektar Therapeutics by 12.4% during the 3rd quarter. Vanguard Group Inc. now owns 23,164,944 shares of the biopharmaceutical company’s stock valued at $74,128,000 after buying an additional 2,559,732 shares during the period. Norges Bank acquired a new stake in shares of Nektar Therapeutics in the 4th quarter valued at $3,835,000. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Nektar Therapeutics by 103.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,550,049 shares of the biopharmaceutical company’s stock valued at $5,762,000 after purchasing an additional 1,297,677 shares during the last quarter. Institutional investors and hedge funds own 92.30% of the company’s stock.

Insider Buying and Selling

In related news, insider Jonathan Zalevsky sold 10,484 shares of the firm’s stock in a transaction that occurred on Thursday, February 16th. The shares were sold at an average price of $3.00, for a total value of $31,452.00. Following the completion of the transaction, the insider now owns 303,179 shares of the company’s stock, valued at approximately $909,537. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Nektar Therapeutics news, CEO Howard W. Robin sold 19,635 shares of Nektar Therapeutics stock in a transaction on Thursday, February 16th. The shares were sold at an average price of $3.00, for a total transaction of $58,905.00. Following the completion of the sale, the chief executive officer now owns 960,158 shares of the company’s stock, valued at approximately $2,880,474. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Jonathan Zalevsky sold 10,484 shares of Nektar Therapeutics stock in a transaction on Thursday, February 16th. The shares were sold at an average price of $3.00, for a total transaction of $31,452.00. Following the sale, the insider now directly owns 303,179 shares of the company’s stock, valued at approximately $909,537. The disclosure for this sale can be found here. In the last 90 days, insiders sold 40,386 shares of company stock valued at $121,158. Company insiders own 3.38% of the company’s stock.

About Nektar Therapeutics

(Get Rating)

Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cancer and autoimmune diseases.